Virtual Library
Start Your Search
F. Watanabe
Author of
-
+
P2.14 - Radiotherapy (ID 715)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Radiotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.14-020a - Retrospective Research on Radiofrequency Ablation (RFA) for Liver Metastasis Due to NSCLC: A Single Institutional Experience (ID 10493)
09:30 - 09:30 | Author(s): F. Watanabe
- Abstract
Abstract not provided
-
+
P3.07 - Immunology and Immunotherapy (ID 723)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.07-013b - The Comparison Analysis of PD-1 Status Between 22C3 and 28-8 IHC Assay in Clinical Practice: A Single Institutional Experience (ID 10499)
09:30 - 09:30 | Author(s): F. Watanabe
- Abstract
Background:
Recently, progress in the treatment of NSCLC patients with PD-L1 expression has been heralded in the field of immune-oncology. Pembrolizumab and Nivolumab are anti-PD-1 (Programmed death) agents used in the treatment of NSCLC patients with PD-L1 expression, and the efficacy of these agents tremendously prolong the overall survival times (OS). Although, the data of concordance for staining each anti-body in clinical course is limited.
Method:
We reviewed all 81 patients who were diagnosed with, or suspected of having NSCLC and received a tissue biopsy between February 2017 and April 2017 in Matsusaka Municipal Hospital. A total of 81 NSCLC tumors were stained with four PD-L1 IHC assays (22C3 and 28-8) The aim of this study was to evaluate the clinical characteristics and to compare concordance between both groups, when divided into three groups as follows; no(negative), low(≧1-49%/1-5%),high(≧50%/≧5%), and to compare the concordance of PD-1 expression between old (stained after 6 months) and fresh (stained within 6months) samples.
Result:
The median age was 75 [range: 58-89], 59 were male, 22(27.1%) were never-smokers. 55(67.9%) and 21(25.9%) patients was diagnosed with adenocarcinoma and squamous cell carcinoma, respectively. Negative/low/high/unevaluable in PD-1 status were 38/21/16/6 and 39/19/18/5 in 22C3 and 22-8, respectively. In both group 22C3 and 22-8 PD-L1 staining group, no significant differences were seen in the characteristics of the results, whether positive or negative. The concordance rate between 22C3 and 28-8 staining was 75% in all stages, 87% in early stage, and 77 % in advance stage cases. The concordance rate of old samples against fresh ones was 75% versus 84%.
Conclusion:
The concordance between 22C3 and 28-8 was high value in clinical practice. This study also demonstrated the similar concordance of PD-1 expression between fresh and old samples, or between early stage and advanced stage.
